Yissum - Research Development Company of the Hebrew University

New Formulations for Oral, Nasal, Transdermal and Rectal of Cannabinoids

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

New Formulations for Oral, Nasal, Transdermal and Rectal of Cannabinoids
Project ID : 6-2017-4448

Description of the technology


Cannabinoids Administration, Formulation, Drug Delivery, Novel Carriers, Transdermal Formulation, Nasal Formulation, Oral formulation

Development Stage

In-vivo proof of concept

Patent Status

Several patent applications – new technologies for various routes of administration


Improved effect of Cannabinoids administrated via different routes is a real need and has increasing demand   


  • There is a need for products cannabinoids based products for treatment via various ways of administration (Nasal, Oral, Transdermal and Rectal), efficient and safe that show prolonged effective action.
  • Currently, Cannabinoids are administrated in capsules or sublingual spray, the drug having only short action (a peak effect up to 4 hours with a median T max up to 2.5 hours).
  • Cannabinoids are very lipophilic molecules.  Hence, in order to bring them to a molecular state (dissolved), solvents like vegetable oils, glycols (propylene glycol) and ethanol are used. 
  • We have designed innovative cannabinoid formulations for the main routes of drug administration (dermal, nasal, oral and rectal) for treatment of various ailments: pain, many neurological diseases, sleep, appetite, mood, anxiety, rheumatic arthritis, inflammatory diseases, and stress.


  • Our new different platform technologies for Cannabinoids do not require oils or chemical   solvents.
  • Eco-friendly preparation process, no need of high heating or use of solvents.
  • The inactive ingredients used in this new dosage form are approved for pharmaceutical use
  • The technology is adequate for various cannabinoids: CBD, THC, iso-THC, CBG, CBC, CBN, CBE, CBL, CBT and their mixtures or for plant extracts.
  • In-vivo proof of concept

Our Innovation

Innovative Formulations and compositions for design and development of new cannabinoid products for treatment of a wide range of diseases.

Key Features

  • Innovative Transdermal, Nasal, Oral and Rectal technologies for the development of new efficient products  of Cannabinoids (CBD, THC, others) for treatment of various diseases
  • IP
  • Excipients approved for pharmaceutical use
  • Eco-friendly processes
  • As an example, experiments in pain animal model following the administration of cannabinoids in the new oral formulation show a very efficient and prolonged antinociceptive effect.

Development Milestones


Seeking investment in new company or industrial collaboration for products development and clinical studies

Project manager

Ariela Markel
VP, Business Development, Healthcare

Project researchers

Elka Touitou
HUJI, School of Medicine - IMRIC
School of Pharmacy- Institute for Drug Research

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Diagnostic
  • Therapeutic
  • Other Medical/Health Related
  • Agro and Marine biotech
  • Anatomy, Pathology, Immunology, Physiology
  • Clinical Medicine
  • Drug delivery
  • Life Science & Biotechnology

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.